Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter, A Arance… - The Lancet …, 2019 - thelancet.com
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …
被引用次数：1036 相关文章

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter… - The Lancet …, 2019 - research.manchester.ac.uk
Background: Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter, A Arance, J Grob… - 2019 - christie.openrepository.com
BACKGROUND: Pembrolizumab improved progression-free survival and overall survival
versus ipilimumab in patients with advanced melanoma and is now a standard of care in the …

[引用][C] Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled …

C Robert, A Ribas, J Schachter, A Arance, JJ Grob… - The Lancet …, 2019 - cir.nii.ac.jp
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year
results from an open-label, multicentre, randomised, controlled, phase 3 study | CiNii Research …

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter, A Arance… - Lancet …, 2019 - researchportal.vub.be
BACKGROUND: Pembrolizumab improved progression-free survival and overall survival
versus ipilimumab in patients with advanced melanoma and is now a standard of care in the …
[PDF] tekinvestor.no

[PDF][PDF] Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled …

C Robert, A Ribas, J Schachter, A Arance, JJ Grob… - 2019 - tekinvestor.no
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter, A Arance… - The Lancet …, 2019 - europepmc.org
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 …

C Robert, A Ribas, J Schachter, A Arance, JJ Grob… - The Lancet …, 2019 - Elsevier
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …
[PDF] amazonaws.com

[PDF][PDF] Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled …

C Robert, A Ribas, J Schachter, A Arance… - 2019 - tekinvestor.s3.dualstack.eu-west-1 …
Background Pembrolizumab improved progression-free survival and overall survival versus
ipilimumab in patients with advanced melanoma and is now a standard of care in the first …